IQV Stock Overview
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
IQVIA Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$227.25 |
| 52 Week High | US$261.73 |
| 52 Week Low | US$167.42 |
| Beta | 1.52 |
| 1 Month Change | -10.49% |
| 3 Month Change | 6.60% |
| 1 Year Change | 12.58% |
| 3 Year Change | 3.77% |
| 5 Year Change | 67.35% |
| Change since IPO | 439.66% |
Recent News & Updates
Is IQVIA Holdings (NYSE:IQV) Using Too Much Debt?
Apr 11
IQVIA Holdings Inc.'s (NYSE:IQV) Share Price Not Quite Adding Up
Mar 27Here's Why IQVIA Holdings (NYSE:IQV) Has Caught The Eye Of Investors
Mar 14Recent updates
Is IQVIA Holdings (NYSE:IQV) Using Too Much Debt?
Apr 11IQVIA Holdings Inc.'s (NYSE:IQV) Share Price Not Quite Adding Up
Mar 27Here's Why IQVIA Holdings (NYSE:IQV) Has Caught The Eye Of Investors
Mar 14IQVIA Holdings: Strong Q4 Results Suggest A Bullish 2024
Feb 22Is IQVIA Holdings Inc. (NYSE:IQV) Trading At A 29% Discount?
Jan 23Market Participants Recognise IQVIA Holdings Inc.'s (NYSE:IQV) Earnings
Dec 24We Think IQVIA Holdings (NYSE:IQV) Can Stay On Top Of Its Debt
Dec 08Should You Investigate IQVIA Holdings Inc. (NYSE:IQV) At US$205?
Nov 23IQVIA Q3: TAS Segment Remains The Problem Child
Nov 21IQVIA: I Would Stay Away Until Debt Issues Are Resolved
Nov 12Is There An Opportunity With IQVIA Holdings Inc.'s (NYSE:IQV) 32% Undervaluation?
Oct 08IQVIA: Stock To Remain Rangebound As I Expect Weak Numbers In The Near Term
Sep 07Is IQVIA Holdings (NYSE:IQV) A Risky Investment?
Sep 04Why IQVIA Holdings Inc. (NYSE:IQV) Could Be Worth Watching
Aug 11IQVIA Holdings Q2: Breaking Ground And Beating Expectations
Aug 03IQVIA Holdings Inc.'s (NYSE:IQV) Intrinsic Value Is Potentially 43% Above Its Share Price
Jun 27IQVIA Holdings (NYSE:IQV) Has A Pretty Healthy Balance Sheet
Jun 05IQVIA Holdings: A Possible Beat And Raise Scenario In The Works
May 23What Does IQVIA Holdings Inc.'s (NYSE:IQV) Share Price Indicate?
May 04A Look At The Fair Value Of IQVIA Holdings Inc. (NYSE:IQV)
Mar 19Does IQVIA Holdings (NYSE:IQV) Have A Healthy Balance Sheet?
Mar 05Here's Why We Think IQVIA Holdings (NYSE:IQV) Might Deserve Your Attention Today
Feb 12IQVIA Q4 2022 Earnings Preview
Feb 09When Should You Buy IQVIA Holdings Inc. (NYSE:IQV)?
Jan 29IQVIA Holdings: Premium Valuation Is Justified For An Industry Leader
Jan 24We Think IQVIA Holdings (NYSE:IQV) Can Stay On Top Of Its Debt
Nov 09IQVIA Holdings Sees Digital Opportunities, But Debt Drags Growth
Nov 02IQVIA Q3 2022 Earnings Preview
Oct 25Is Now The Time To Look At Buying IQVIA Holdings Inc. (NYSE:IQV)?
Oct 02IQVIA: Rebound Is Likely But Downtrend Is Still Intact (Technical Analysis)
Sep 19With EPS Growth And More, IQVIA Holdings (NYSE:IQV) Makes An Interesting Case
Aug 22GSK, Iqvia launch Vaccine Track platform to highlight vaccine trends publicly in US
Aug 11We Think IQVIA Holdings (NYSE:IQV) Can Stay On Top Of Its Debt
Aug 08IQVIA: Resiliency And Quality Never Left, Q2 Earnings Evidence The Same
Jul 28Are Investors Undervaluing IQVIA Holdings Inc. (NYSE:IQV) By 48%?
Jul 26IQVIA Non-GAAP EPS of $2.44 beats by $0.06, revenue of $3.54B beats by $50M, raises FY22 guidance
Jul 21IQVIA A Smart Choice In A High-Inflation Environment
Apr 29When Should You Buy IQVIA Holdings Inc. (NYSE:IQV)?
Mar 28Here's Why We Think IQVIA Holdings (NYSE:IQV) Is Well Worth Watching
Mar 01IQVIA: Intelligent Healthcare Solutions For A Growing Market
Feb 19IQVIA Holdings (NYSE:IQV) Seems To Use Debt Quite Sensibly
Feb 17Is Now An Opportune Moment To Examine IQVIA Holdings Inc. (NYSE:IQV)?
Dec 16Is There An Opportunity With IQVIA Holdings Inc.'s (NYSE:IQV) 33% Undervaluation?
Dec 01Shareholder Returns
| IQV | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -5.1% | -4.9% | -3.7% |
| 1Y | 12.6% | -4.3% | 20.5% |
Return vs Industry: IQV exceeded the US Life Sciences industry which returned -6.3% over the past year.
Return vs Market: IQV underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| IQV volatility | |
|---|---|
| IQV Average Weekly Movement | 4.8% |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IQV has not had significant price volatility in the past 3 months.
Volatility Over Time: IQV's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 87,000 | Ari Bousbib | www.iqvia.com |
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
IQVIA Holdings Inc. Fundamentals Summary
| IQV fundamental statistics | |
|---|---|
| Market cap | US$41.71b |
| Earnings (TTM) | US$1.36b |
| Revenue (TTM) | US$14.98b |
30.5x
P/E Ratio2.8x
P/S RatioIs IQV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IQV income statement (TTM) | |
|---|---|
| Revenue | US$14.98b |
| Cost of Revenue | US$9.75b |
| Gross Profit | US$5.24b |
| Other Expenses | US$3.88b |
| Earnings | US$1.36b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | 7.46 |
| Gross Margin | 34.96% |
| Net Profit Margin | 9.06% |
| Debt/Equity Ratio | 224.5% |
How did IQV perform over the long term?
See historical performance and comparison